Page last updated: 2024-11-13

methocinnamox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methocinnamox: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46877713
CHEMBL ID610884
MeSH IDM0369159

Synonyms (6)

Synonym
CHEMBL610884
mcam
methocinnamox
117339-76-1
(e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-methylphenyl)prop-2-enamide
GLXC-25817

Research Excerpts

Overview

Methocinnamox (MCAM) is a novel, long-acting opioid receptor antagonist. MCAM might be an effective treatment for opioid use disorder.

ExcerptReferenceRelevance
"Methocinnamox (MCAM) is a novel, long-acting opioid receptor antagonist that might be an effective treatment for opioid use disorder (i.e., preventing relapse and overdose)."( Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys.
France, CP; Maguire, DR, 2024
)
2.64

Dosage Studied

ExcerptRelevanceReference
"8 mg/kg) produced a 74-fold increase in the ED(50) of morphine while showing no effect on bremazocine or BW373U86 dose-response curves."( Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear, JH; Burke, TF; Husbands, SM; Lewis, JW; Sumpter, TL; Traynor, JR; Woods, JH, 2000
)
1.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID269592Antagonist activity against morphine-induced antinociception in sc dosed mouse by tail flick assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
AID269588Agonist activity in sc dosed mouse by phenylquinone abdominal stretching assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
AID269587Agonist activity in sc dosed mouse by tail flick assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
AID269594Agonist activity in mouse by hot water tail withdrawal assay at 32 mg/kg, sc2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
AID269597Antagonist activity against morphine-induced antinociception in sc dosed mouse by hot water tail withdrawal assay at 32 mg/kg, sc2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
AID1054689Selectivity ratio of Ki for human delta opioid receptor to Ki for human mu opioid receptor2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
AID1054688Selectivity ratio of Ki for human kappa opioid receptor to Ki for human mu opioid receptor2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's2 (18.18)24.3611
2020's6 (54.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.92 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]